BETA: Please send your feedback!
Haemato
HAE-DE:ETR
Pharmaceuticals: Generic
—
MICRO cap
(—)
—
since start of 2021
—
- 1
- 1
- 1
- —
- 1
- 3
- 1
- 5
- —
- —
- —
- 3
-
Carbon Footprint
-
Pollution Prevention
-
Water Conservation
-
Data & Privacy Protection
-
Consumer Health, Wellness & Safety
-
Employee Ownership, Satisfaction, Benefits & Pay
-
Workplace Health and Safety
-
Integrity of Corporate Governance
-
Ethical Practices
-
Usage of Conflict Materials
-
Forced Labor
-
Diversity of Corporate Leadership
About
Pharmaceuticals: Generic
Founded 1993
Haemato AG engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes generics for aids, neurology, oncology, rheumatology, and urology diseases. The company was founded on May 10, 1993 and is headquartered in Schönefeld, Germany.
website
Headquarters
Executives
Name | Title | Gender |
Andrea Grosse | Chairman-Supervisory Board | Female |
Mindful Investing Summary
Haemato - Competitors and Related Companies
How Haemato stacks up to its peers in the Pharmaceuticals: Generic industry or with competing business segments.
Haemato
HAE-DE:ETR
Pharmaceuticals: Generic
—
MICRO cap
(—)
—
since start of 2021
—
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
-
Carbon Footprint
-
Pollution Prevention
-
Water Conservation
-
Data & Privacy Protection
-
Consumer Health, Wellness & Safety
-
Employee Ownership, Satisfaction, Benefits & Pay
-
Workplace Health and Safety
-
Integrity of Corporate Governance
-
Ethical Practices
-
Usage of Conflict Materials
-
Forced Labor
-
Diversity of Corporate Leadership
Loading…